Press Release Jan 10 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Febuxostat Tablets. These tablets are used to treat high uric acid levels in patients with gout who cannot use allopurinol. The drug will be manufactured at the company's facility in Ahmedabad, India. The press release also notes that Febuxostat tablets had significant annual sales in the United States according to market data.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 06 2023
- Press Release Dec 30 2022
- Loss of Share Certificates
- Press Release Dec 22 2022
- Press Release Dec 10 2022
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jan 12 2023
- Zydus Lifesciences Limited Press Release Jan 16 2023
- Press Release Jan 27 2023
- Press Release Feb 15 2023
- Zydus Lifesciences Limited Press Release Feb 17 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences